Company profile: Annovis Bio
1.1 - Company Overview
Company description
- Provider of treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders, including: Buntanetap, an oral small molecule inhibiting multiple neurotoxic proteins; ANVS405, an IV formulation for acute neurodegeneration like TBI and stroke; and ANVS301, a Phase 1 compound aiming to increase cognitive capabilities in later-stage Alzheimer’s and dementia.
Products and services
- ANVS301: Phase‑1 compound engineered to increase cognitive capabilities in later-stage Alzheimer’s disease and dementia, targeted for progressive neurodegeneration
- ANVS405: Intravenous formulation developed for acute neurodegeneration, including TBI and stroke, of the compound used in chronic conditions
- Buntanetap: Small‑molecule, orally available product engineered for Alzheimer’s disease and Parkinson’s disease, inhibiting multiple neurotoxic proteins implicated in those disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Annovis Bio
IntraBio
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and candidates, including IB1001 (orally administered N-Acetyl-Leucine) for rare neurological disorders such as NPC, GM1/GM2 gangliosidosis and inherited cerebellar ataxias; IB2000 and IB5000 for Ménière’s disease with clinical efficacy and safety in observational studies; IB3000 (NAADP analogues/agonists) with pre-clinical potential for Type 2 Diabetes, autism and neurodegenerative disorders; IB4000 (UDCA) for NPC liver dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntraBio company profile →
Disarm Therapeutics
HQ: United States
Website
- Description: Provider of disease-modifying therapeutics for patients with axonal degeneration, developing drugs that prevent axon loss and treat neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Disarm Therapeutics company profile →
Mika Pharma
HQ: Germany
Website
- Description: Provider of innovative drug delivery technologies for pharmaceuticals, developing, producing, and selling dermal, transdermal, and buccal application systems based on sprayable liposomes, pre-liposomal solutions, and proprietary micellar solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mika Pharma company profile →
Aelis Farma
HQ: France
Website
- Description: Provider of signaling-specific therapeutics targeting GPCRs, notably the CB1 receptor, including AEF0117 for cannabis-related disorders, AEF0217 for cognitive deficits (initially Down syndrome, with potential for Fragile X syndrome and aging), and CB1-SSi inhibitors that selectively inhibit pathological CB1 hyperactivity without affecting normal brain functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aelis Farma company profile →
Psyadon
HQ: United States
Website
- Description: Provider of discovery and development of new treatments for serious psychiatric and neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Psyadon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Annovis Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Annovis Bio
2.2 - Growth funds investing in similar companies to Annovis Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Annovis Bio
4.2 - Public trading comparable groups for Annovis Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →